Elutia Inc (ELUT)

$1.15 -0.02 (-1.71%)
Market Cap 50.06M
Revenue (ttm) 12.29M
Net Income (ttm) 53.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 434.34%
Debt to Equity Ratio -0.59
Volume 37,800
Avg Vol 140,466
Day's Range N/A - N/A
Shares Out 42.79M
Stochastic %K 67%
Beta 0.71
Analysts Strong Sell
Price Target $5.00

Company Profile

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for ca...

Industry: Medical Devices
Sector: Healthcare
Phone: 240 247 1170
Fax: 510 307 9896
Website: elutia.com
Address:
20 Firstfield Road, Gaithersburg, United States
SuperGreenToday
SuperGreenToday Apr. 7 at 6:47 PM
$ELUT
0 · Reply
Invest2live
Invest2live Apr. 4 at 1:22 AM
$ELUT 59% already; congrats 🌿🎈🌿 Checkout $GAU and $RXRX
0 · Reply
Maydate8
Maydate8 Apr. 3 at 12:46 AM
$ELUT one that is undervalued
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 1 at 6:17 PM
$ELUT RSI: 46.07, MACD: 0.0047 Vol: 0.03, MA20: 1.09, MA50: 1.06 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Sidoti
Sidoti Mar. 20 at 10:09 PM
Elutia Inc. ($ELUT) Management Team presented at the Sidoti Small-Cap Virtual Conference this week. Watch the replay here: https://sidoti.zoom.us/webinar/register/WN_bckjL702SRKzQIv2dFlBOg
0 · Reply
Sidoti
Sidoti Mar. 19 at 6:50 PM
Presenting now at the virtual #SidotiConference $ELUT $STKS https://www.meetmax.com/sched/event_132523/conference_presentations.html
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 11 at 9:54 PM
$ELUT Q4 '25 Earnings Results & Recap Elutia anticipates FDA clearance for its base biologic matrix NXT-41 in the second half of 2026, with full NXT-41x drug-eluting biologic clearance expected in the first half of 2027.
0 · Reply
EyeYamStewPeed
EyeYamStewPeed Mar. 11 at 8:34 PM
$ELUT what a joke; pump n dump
0 · Reply
palo34
palo34 Mar. 11 at 8:32 PM
$ELUT my best performing stock, but got small and added few dollars here and there. I did not anticipate consistant growth.
0 · Reply
TheTradeXchange
TheTradeXchange Mar. 4 at 1:02 PM
$ELUT - Elutia Regains Compliance with Nasdaq Listing Requirements
0 · Reply
Latest News on ELUT
Elutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19

Mar 17, 2026, 8:00 AM EDT - 4 weeks ago

Elutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Mar 13, 2026, 8:00 AM EDT - 5 weeks ago

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process

Mar 11, 2026, 4:05 PM EDT - 5 weeks ago

Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process

Elutia Regains Compliance with Nasdaq Listing Requirements

Mar 4, 2026, 8:00 AM EST - 6 weeks ago

Elutia Regains Compliance with Nasdaq Listing Requirements

Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

Mar 2, 2026, 8:00 AM EST - 6 weeks ago

Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026

Feb 25, 2026, 4:05 PM EST - 7 weeks ago

Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026

Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™

Feb 18, 2026, 8:00 AM EST - 2 months ago

Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™

Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones

Jan 12, 2026, 8:00 AM EST - 3 months ago

Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones

Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery

Jan 9, 2026, 8:00 AM EST - 3 months ago

Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery

Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development

Nov 6, 2025, 4:05 PM EST - 5 months ago

Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development

Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Oct 23, 2025, 4:05 PM EDT - 6 months ago

Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21

Oct 14, 2025, 4:05 PM EDT - 6 months ago

Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21

Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors

Oct 10, 2025, 8:00 AM EDT - 6 months ago

Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors

Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million

Oct 1, 2025, 8:41 AM EDT - 7 months ago

Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million

Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation

Sep 16, 2025, 8:00 AM EDT - 7 months ago

Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation

Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million

Sep 9, 2025, 8:30 AM EDT - 7 months ago

Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million

Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange

Sep 4, 2025, 8:00 AM EDT - 8 months ago

Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange

Elutia to Participate in Upcoming Investor Conferences

Aug 27, 2025, 8:00 AM EDT - 8 months ago

Elutia to Participate in Upcoming Investor Conferences

Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption

Aug 14, 2025, 4:05 PM EDT - 8 months ago

Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption

Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Jul 31, 2025, 4:05 PM EDT - 9 months ago

Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Dr. Michelle LeRoux Williams Earns Washington Business Journal's Medical Device Innovator Award

Jul 31, 2025, 8:00 AM EDT - 9 months ago

Dr. Michelle LeRoux Williams Earns Washington Business Journal's Medical Device Innovator Award

New Evidence Supports the Value of Elutia's Antibiotic-Eluting Platform for Implantable Devices

Jul 1, 2025, 8:00 AM EDT - 10 months ago

New Evidence Supports the Value of Elutia's Antibiotic-Eluting Platform for Implantable Devices

Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards

Jun 26, 2025, 8:00 AM EDT - 10 months ago

Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards

Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method

May 28, 2025, 8:00 AM EDT - 11 months ago

Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method

Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales

May 8, 2025, 4:05 PM EDT - 1 year ago

Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales

Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio

May 1, 2025, 4:05 PM EDT - 1 year ago

Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio

Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025

Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29

Apr 22, 2025, 4:05 PM EDT - 1 year ago

Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29

Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice

Elutia Confirms No Material Impact from Global Tariffs

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Elutia Confirms No Material Impact from Global Tariffs

Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biology Makes

Apr 2, 2025, 4:05 PM EDT - 1 year ago

Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biology Makes

Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™

Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope

Mar 25, 2025, 4:05 PM EDT - 1 year ago

Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope

Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out

Mar 6, 2025, 4:05 PM EST - 1 year ago

Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out

Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025

Feb 20, 2025, 4:05 PM EST - 1 year ago

Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025

Elutia Announces $15.0 Million Registered Direct Offering

Feb 3, 2025, 6:30 AM EST - 1 year ago

Elutia Announces $15.0 Million Registered Direct Offering

Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30

Oct 23, 2024, 4:05 PM EDT - 1 year ago

Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30

Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company's Antibiotic-Eluting BioEnvelope for Implantable Devices

Sep 18, 2024, 8:00 AM EDT - 1 year ago

Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company's Antibiotic-Eluting BioEnvelope for Implantable Devices

Elutia Celebrates First Year

Sep 6, 2024, 4:23 PM EDT - 1 year ago

Elutia Celebrates First Year

Elutia Announces First Patient Implant of EluPro™, the World's First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Elutia Announces First Patient Implant of EluPro™, the World's First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD EUDA GDTC GOSS GOVX IMRN

Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

Elutia to Present at the Emerging Growth Conference on Thursday, July 18

Jul 11, 2024, 4:05 PM EDT - 1 year ago

Elutia to Present at the Emerging Growth Conference on Thursday, July 18

Elutia Announces $13.26 Million Registered Direct Offering

Jun 17, 2024, 8:01 AM EDT - 1 year ago

Elutia Announces $13.26 Million Registered Direct Offering

Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators

Jun 17, 2024, 8:00 AM EDT - 1 year ago

Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators

Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1

Apr 24, 2024, 4:05 PM EDT - 2 years ago

Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1

Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024

Mar 7, 2024, 4:05 PM EST - 2 years ago

Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024

Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024

Feb 22, 2024, 4:05 PM EST - 2 years ago

Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024

Elutia Reports 26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial Results

Nov 13, 2023, 4:05 PM EST - 2 years ago

Elutia Reports 26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial Results

Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million

Nov 9, 2023, 8:30 AM EST - 2 years ago

Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million

SuperGreenToday
SuperGreenToday Apr. 7 at 6:47 PM
$ELUT
0 · Reply
Invest2live
Invest2live Apr. 4 at 1:22 AM
$ELUT 59% already; congrats 🌿🎈🌿 Checkout $GAU and $RXRX
0 · Reply
Maydate8
Maydate8 Apr. 3 at 12:46 AM
$ELUT one that is undervalued
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 1 at 6:17 PM
$ELUT RSI: 46.07, MACD: 0.0047 Vol: 0.03, MA20: 1.09, MA50: 1.06 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Sidoti
Sidoti Mar. 20 at 10:09 PM
Elutia Inc. ($ELUT) Management Team presented at the Sidoti Small-Cap Virtual Conference this week. Watch the replay here: https://sidoti.zoom.us/webinar/register/WN_bckjL702SRKzQIv2dFlBOg
0 · Reply
Sidoti
Sidoti Mar. 19 at 6:50 PM
Presenting now at the virtual #SidotiConference $ELUT $STKS https://www.meetmax.com/sched/event_132523/conference_presentations.html
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 11 at 9:54 PM
$ELUT Q4 '25 Earnings Results & Recap Elutia anticipates FDA clearance for its base biologic matrix NXT-41 in the second half of 2026, with full NXT-41x drug-eluting biologic clearance expected in the first half of 2027.
0 · Reply
EyeYamStewPeed
EyeYamStewPeed Mar. 11 at 8:34 PM
$ELUT what a joke; pump n dump
0 · Reply
palo34
palo34 Mar. 11 at 8:32 PM
$ELUT my best performing stock, but got small and added few dollars here and there. I did not anticipate consistant growth.
0 · Reply
TheTradeXchange
TheTradeXchange Mar. 4 at 1:02 PM
$ELUT - Elutia Regains Compliance with Nasdaq Listing Requirements
0 · Reply
Invest2live
Invest2live Feb. 24 at 7:00 PM
$ELUT 59% already; congrats 🎈 🌿; anything below 1.30 is cheap for $HUMA.
0 · Reply
Geddymd72
Geddymd72 Feb. 21 at 1:11 AM
$ELUT Got in small at 0.75 last month. Biotech companies are risky. Get them while they are cheap and dont lose your shirt.
0 · Reply
algo888
algo888 Feb. 19 at 4:58 PM
$GERN $ERNA $IMUX $ELUT Go ALL in now on IMUX Inching up closer and closer to the high of day breakout..
0 · Reply
lucidi
lucidi Feb. 18 at 5:00 PM
$ELUT already up over 100%. looks like it is just getting started. glta
0 · Reply
S2K_TP
S2K_TP Feb. 15 at 5:26 AM
$ELUT on watch 🦉
1 · Reply
Invest2live
Invest2live Feb. 14 at 12:01 AM
$ELUT 51% in a month already; congrats 🌿🎈🌿 Checkout $HUMA and $GERN
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 13 at 2:07 PM
$ELUT RSI: 50.11, MACD: 0.0497 Vol: 0.07, MA20: 0.96, MA50: 0.77 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
GammaGrid
GammaGrid Feb. 9 at 2:20 PM
$ELUT E-liquid or vaping products; faces intense regulatory scrutiny.
0 · Reply